IFRX N Stock Overview
A clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
InflaRx N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$24.74 |
| 52 Week High | US$27.00 |
| 52 Week Low | US$24.74 |
| Beta | 1.58 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -72.20% |
| 5 Year Change | -52.27% |
| Change since IPO | -95.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| IFRX N | MX Biotechs | MX Market | |
|---|---|---|---|
| 7D | 0% | 0% | 0% |
| 1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how IFRX N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how IFRX N performed against the MX Market.
Price Volatility
| IFRX N volatility | |
|---|---|
| IFRX N Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 0% |
| Market Average Movement | 0% |
| 10% most volatile stocks in MX Market | 0% |
| 10% least volatile stocks in MX Market | 0% |
Stable Share Price: IFRX N's share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine IFRX N's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 62 | Niels Riedemann | www.inflarx.de |
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
InflaRx N.V. Fundamentals Summary
| IFRX N fundamental statistics | |
|---|---|
| Market cap | Mex$1.89b |
| Earnings (TTM) | -Mex$1.03b |
| Revenue (TTM) | Mex$2.32m |
813.9x
P/S Ratio-1.8x
P/E RatioIs IFRX N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IFRX N income statement (TTM) | |
|---|---|
| Revenue | €105.48k |
| Cost of Revenue | €1.10m |
| Gross Profit | -€995.45k |
| Other Expenses | €45.89m |
| Earnings | -€46.88m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | -0.80 |
| Gross Margin | -943.71% |
| Net Profit Margin | -44,447.49% |
| Debt/Equity Ratio | 0% |
How did IFRX N perform over the long term?
See historical performance and comparison